Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase NA 1Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 375Neoplasms 324Neoplasm Metastasis 288Leukemia, Myeloid, Acute 282Breast Neoplasms 273Colorectal Neoplasms 238Melanoma 196Ovarian Neoplasms 191Recurrence 187Multiple Myeloma 180Prostatic Neoplasms 156Lung Neoplasms 156Pancreatic Neoplasms 153Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 120Myelodysplastic Syndromes 117Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 108Advanced Solid Tumors 108Brain Neoplasms 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma 103Lymphoma, Large B-Cell, Diffuse 102Lymphoma, B-Cell 98Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 91

Interventions

defactinib 1RO5126766 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Endometrioid × 1 year × Clear all
NCT03875820 2026-03-10

FRAME

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting
87 enrolled
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Endometrioid

NCT03748186 2025-08-20

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Sutro Biopharma, Inc.

Phase 1 Completed
136 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡